Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Sibrafiban"'
Publikováno v:
Fibrinolytic and Antithrombotic Therapy : Theory, Practice, and Management, 2006.
Externí odkaz:
https://doi.org/10.1093/oso/9780195155648.003.0014
Autor:
Svati H. Shah, Darren K. McGuire, W. Douglas Weaver, Paul W. Armstrong, Philip E. Aylward, L. Kristin Newby, Manjushri Bhapkar, A Kristinsson, Camille G. Frazier, Werner Klein, Zygmunt Sadowski
Publikováno v:
American Heart Journal. 150:1260-1267
Background Hypertension affects 1 billion individuals worldwide and is an independent risk factor for death after acute coronary syndromes (ACS). Methods We examined the prevalence and medical treatment of hypertension among 15 904 ACS patients rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f03d7726bc22205505d9a103a9e6002b
https://doi.org/10.1016/j.ahj.2005.08.004
https://doi.org/10.1016/j.ahj.2005.08.004
Publikováno v:
American Journal of Therapeutics. 11:302-307
The integrin glycoprotein IIb/IIIa receptor is the final common pathway to platelet aggregation. Administration of glycoprotein IIb/IIIa receptor antagonists reduces acute ischemic complications following plaque fissuring or rupture. Research on this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6de53aed77405ba07d5adf0beaa0626e
https://doi.org/10.1097/01.mjt.0000071284.87458.a4
https://doi.org/10.1097/01.mjt.0000071284.87458.a4
Autor:
Dalia M. Araujo, Paul A. Lapchak
Publikováno v:
American Journal of Cardiovascular Drugs. 3:87-94
The only drug approved by the US FDA for use in patients with acute ischemic stroke is the thrombolytic, alteplase. Whereas alteplase rapidly restores blood flow, the drug has to be administered within 6 hours after symptom onset and is associated wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddc38416ba7c490e31ad051a599591f2
https://doi.org/10.2165/00129784-200303020-00002
https://doi.org/10.2165/00129784-200303020-00002
Autor:
Shaker A. Mousa, Mark S. Forsythe
Publikováno v:
Thrombosis Research. 104:49-56
The effect of various platelet glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists on the dynamics of platelet–fibrin clot formation and strength induced by various stimuli was measured by thromboelastography (TEG). GPIIb/IIIa antagonists with high affi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78e0d86d6b1f3449fdb345e22edcded4
https://doi.org/10.1016/s0049-3848(01)00336-x
https://doi.org/10.1016/s0049-3848(01)00336-x
Publikováno v:
British Journal of Pharmacology. 133:331-336
A number of non-peptide orally active RGD mimetic prodrug such as Orbofiban, Sibrafiban, SR121566, Roxifiban and others entered into the clinical evaluation stage. Some of these agents were terminated and some are still in clinical trials. The presen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::586dd6b0f5b8ae34a9f439c0d0255486
https://doi.org/10.1038/sj.bjp.0703943
https://doi.org/10.1038/sj.bjp.0703943
Publikováno v:
Circulation. 103:1727-1733
Background —The first Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post–Acute Coronary Syndromes (SYMPHONY) trial showed no benefit of 2 doses of sibrafiban over aspirin for secondary prevention after acute cor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f053a1fc47f9b954ee80232c55bf0dad
https://doi.org/10.1161/01.cir.103.13.1727
https://doi.org/10.1161/01.cir.103.13.1727
Publikováno v:
Circulation. 103:201-206
Background —Numerous clinical trials have established the benefits of intravenous glycoprotein IIb/IIIa inhibition in the management of coronary artery disease. In contrast, the recent large-scale, placebo-controlled, randomized trials of the oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce9fdd792ba01ed3875248d262e93062
https://doi.org/10.1161/01.cir.103.2.201
https://doi.org/10.1161/01.cir.103.2.201
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 20:1162-1167
Abstract —In the present study, the in vitro efficacy of different platelet glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists on platelet-fibrin–mediated clot strength under shear was compared with the antiaggregatory efficacy by using tissue factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84d8009d3bdc41839f9397759bac7992
https://doi.org/10.1161/01.atv.20.4.1162
https://doi.org/10.1161/01.atv.20.4.1162
Autor:
Samuel J. Machin, Herbert Birnböck, Bärbel Wittke, Jain Chung, Ian Mackie, Hilary Ensor, Sylvie I. Ertel, Berthold Lausecker
Publikováno v:
British Journal of Clinical Pharmacology. 49:231-239
Aims The purpose of this clinical study was to evaluate the effects of a ticlopidine/aspirin combination on the pharmacokinetics and pharmacodynamics of sibrafiban and the tolerability of the combination therapy Methods Thirty-eight healthy male volu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6605514dd1ade17a3bde70839940b7ec
https://doi.org/10.1046/j.1365-2125.2000.049003231.x
https://doi.org/10.1046/j.1365-2125.2000.049003231.x